STOCK TITAN

Vir Biotechnology grants CFO 150K stock options

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(Neutral)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
4

Rhea-AI Filing Summary

Vir Biotechnology, Inc. granted EVP, Chief Financial Officer Aziz Sawaf 75,000 restricted stock units (RSUs) and stock options covering 150,000 common shares on November 15, 2026. The options have a $9.96 exercise price and expire November 14, 2036. Twenty-five percent of each award vests on November 15, 2027; the remaining RSUs vest in three equal annual installments, while the remaining options vest and become exercisable in 36 equal monthly installments.

Insider Sawaf Aziz
Role EVP, Chief Financial Officer
Type Security Shares Price Value
Grant/Award Stock Option (Right to Buy) F3 150,000 $0.00 $0.00
Grant/Award Common Stock F1, F2 75,000 $0.00 $0.00
Holdings After Transaction: Stock Option (Right to Buy) — 150,000 options (Direct); Common Stock — 75,000 shares (Direct)
Footnotes (3)
  1. F1. Acquisition of restricted stock units (RSUs) pursuant to the Issuer's Equity Incentive Plan.
  2. F2. 25% of the RSUs will vest on November 15, 2027, and the remaining RSUs will vest in three equal annual installments thereafter.
  3. F3. 25% of the shares subject to the stock option will vest and become exercisable on November 15, 2027, and the remaining shares will vest and become exercisable in 36 equal monthly installments thereafter.
RSUs granted 75,000 RSUs Awarded November 15, 2026; 75,000 shares reported following the transaction
Options granted 150,000 shares Stock options awarded November 15, 2026, covering common shares
Exercise price $9.96 per share Stock option award
Option expiration date November 14, 2036 Stock option award
Initial vesting 25% Of each award vests on November 15, 2027
Remaining option vesting 36 equal monthly installments Options vest and become exercisable after the initial vesting date
Remaining RSU vesting 3 equal annual installments After the initial vesting date
restricted stock units (RSUs) financial
"Acquisition of restricted stock units (RSUs) pursuant to the Issuer's Equity Incentive Plan."
Restricted stock units (RSUs) are a type of company promise to give employees shares of stock in the future, usually after certain conditions like working for a set time. They are like a gift promised today that you receive later, which can become valuable if the company's stock price goes up. RSUs matter because they are a way companies reward employees and can be a significant part of compensation.
Equity Incentive Plan financial
"pursuant to the Issuer's Equity Incentive Plan"
An equity incentive plan is a program that gives employees, executives or directors the right to receive company stock or options to buy stock as part of their pay. Think of it as offering slices of future company profit to motivate people to boost long‑term performance; for investors it matters because it can align employee goals with shareholder value but also increases the number of shares outstanding, which can dilute existing ownership.
exercisable technical
"will vest and become exercisable on November 15, 2027"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How do Aziz Sawaf's VIR equity awards vest?

Aziz Sawaf's 75,000 RSUs vest 25% on November 15, 2027, with the remaining RSUs vesting in three equal annual installments thereafter. Of the options covering 150,000 shares, 25% vest and become exercisable on that date, with the remaining options vesting and becoming exercisable in 36 equal monthly installments thereafter.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
X
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Sawaf Aziz

(Last)(First)(Middle)
C/O VIR BIOTECHNOLOGY, INC.
1800 OWENS STREET, SUITE 900

(Street)
SAN FRANCISCO CALIFORNIA 94158

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
Vir Biotechnology, Inc. [ VIR ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director10% Owner
XOfficer (give title below)Other (specify below)
EVP, Chief Financial Officer
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
11/15/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock11/15/2026A(1)75,000(2)A$075,000D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Stock Option (Right to Buy)$9.9611/15/2026A150,000 (3)11/14/2036Common Stock150,000$0150,000D
Explanation of Responses:
1. Acquisition of restricted stock units (RSUs) pursuant to the Issuer's Equity Incentive Plan.
2. 25% of the RSUs will vest on November 15, 2027, and the remaining RSUs will vest in three equal annual installments thereafter.
3. 25% of the shares subject to the stock option will vest and become exercisable on November 15, 2027, and the remaining shares will vest and become exercisable in 36 equal monthly installments thereafter.
Remarks:
/s/ Vanina de Verneuil, Attorney-In-Fact11/16/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Keep reading